Autoregulation: mediators and renin–angiotensin system in diseases and treatments

[11] Aras-López R(1990)Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension Circulation 81 10372-2933

[12] Arroyo-Villa I(2021)Cyclic gmp in liver cirrhosis—role in pathophysiology of portal hypertension and therapeutic implications Int J Mol Sci 22 2928-8

[13] Del Campo L(2000)Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses Proc Natl Acad Sci 97 273-876

[14] Salaices M(2010)The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension Vascular Health Risk Manag 6 1-396

[15] Rossoni LV(2022)A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach Crit Care 26 851-28

[16] Ferrer M(2001)Endothelin system: the double-edged sword in health and disease Annu Rev Pharmacol Toxicol 41 391-203

[17] Balfagón G(2014)Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension Life Sci 118 16-102

[18] Sampaio WO(2011)Endothelin-1 gene regulation FASEB J 25 195-914

[19] Souza dos Santos RA(2011)Endothelin Cell Mol Life Sci 68 91-268

[20] Faria-Silva R(1996)Molecular pharmacology of endothelin converting enzymes Biochem Pharmacol 51 908-S83

[11] Aras-López R(1990)Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension Circulation 81 10372-2933

[12] Arroyo-Villa I(2021)Cyclic gmp in liver cirrhosis—role in pathophysiology of portal hypertension and therapeutic implications Int J Mol Sci 22 2928-8

[13] Del Campo L(2000)Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses Proc Natl Acad Sci 97 273-876

[14] Salaices M(2010)The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension Vascular Health Risk Manag 6 1-396

[15] Rossoni LV(2022)A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach Crit Care 26 851-28

[16] Ferrer M(2001)Endothelin system: the double-edged sword in health and disease Annu Rev Pharmacol Toxicol 41 391-203

[17] Balfagón G(2014)Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension Life Sci 118 16-102

[18] Sampaio WO(2011)Endothelin-1 gene regulation FASEB J 25 195-914

[19] Souza dos Santos RA(2011)Endothelin Cell Mol Life Sci 68 91-268

[20] Faria-Silva R(1996)Molecular pharmacology of endothelin converting enzymes Biochem Pharmacol 51 908-S83